Highlights from Day 1 of ASH 2024 Annual Meeting and Exposition

The 66th American Society of Hematology (ASH) Annual Meeting and Exposition is being held from December 7th-10th, 2024, at the San Diego Convention Center in San Diego, California.

The ASH annual meeting serves as a major gathering for hematology professionals, attracting over 28,000 attendees, including clinicians, scientists, and researchers from across the globe. This meeting is the world’s largest and most comprehensive hematology event of the year.

With hundreds of sessions covering the latest trends in hematology, ASH provides attendees with numerous opportunities to engage with cutting-edge research and developments. Education Program sessions feature didactic presentations, panel discussions, and interactive question-and-answer segments with all the speakers. The event stands out as the premier gathering for hematology professionals worldwide.

Vincent Rajkumar:

“Always great to catch up with dear friends Ken Anderson and Nikhil Munshi.

25th year of collaboration for me with these two greats.”

Talha Badar:

“Dr. Zeidan presented KOMET-07 data with high response rate 100% and >80% with triplet combos in NPM1m and KMT2Ar.”

Naveen Pemmaraju:

“Kudos to our faculty speakers and to all who attended and supported our ASH Education Session on Rare Myeloid Neoplasms yest featuring our talks on BPDCN, CSF3R-expressing malignancies and acute leukemia of ambiguous lineage!!”

Aaron Goodman:

“ASH Education Book

For the general hematologist who still does all including some classical, BMT, cell therapy I read this book every year. Between this book, twitter, and reading about my patients it’s how I keep up.”

Eddie Cliff:

“ASCT is dead! Long live ASCT!

Headline results of updated TRIANGLE study results from Martin Dreyling EMCL network

Overall survival benefit ~10% for both ibrutinib-containing arms over ASCT alone

Little benefit to ASCT.

Practice-changing result.”

Vincent Rajkumar:

“Congrats to my colleagues Juli Perez Bot and Joselle Cook for an outstanding job as Editor and Deputy Editor of ASH News Daily.”

Rahul Banerjee:

“Grateful to our ever-growing Fred Hutchinson Cancer Center myeloma group at ASH24!

Missing Madhav Dhodapkar who had just left – excited for future collaborations!

(And yes – if you’re wondering whether that’s a Christmas-themed Space Needle behind us, why yes it is Christmas tree.)”

Mehdi Hamadani:

“CD19.20 dual CAR in third or later line DLBCL being presented by Nirav Shah.”

Aref Al-Kali:

“Very rich presentation on types of prior Rx impact on imetelstat response as 2L for LR-MDS

– Response was similar regardless of prior Rx
– prior HMA had low ORR
– number of prior Rx impacted ORR.”

Esha Kaul:

“Dr. Dipti Jain delivering the prestigious Ham- Wasseeman lecture.”

Joshua Zeidner:

“Fantastic presentation by Curtis Lachowiez showing the significant prognostic influence of monocytic phenotypes in pts treated with Aza/Ven. In NPM1 wt, monocytic phenotypes led to significantly worse outcomes. Differentiation state should be incorporated into our risk scores.

Proud to work on this impactful project along with Daniel Peters, UNC Lineberger and Daniel Pollyea.”

Andres Gomez:

“Our home at ASH24 is in the 900s, no line for beer, plus all the interesting stuff is down here. Including the new MedEd category, like this poster done in partnership with Oncology Brothers.”

Caner Saygin:

“So proud of these amazing mentees presenting their exciting leukemia research at ASH24.”

Mohamad Mohty:

“When less is more… Looking forward to the results of this practice-changing trial!”

Supriya Peshin: 

“Captured some good shots at ASH24. We are hemeOnc buddies.”

Nihar Desai:

“Phenomenal talk by my friend Nico Gagelmann.

One of the most difficult diseases to transplant. Beautiful talk, Nico.”

Graham Collins:

“Dreyling: longer FU of Triangle (55mo)
– Signif OS benefit of Ibr containing arms
– FFS: ASCT+ibr superior to ASCT
– FFS: Ibr looks superior to ASCT
– ASCT maybe important for high Ki67 / blastoid / p53 abn
– ASCT comes at a tox cost.”

John P. Leopard:

“We have several scenarios in chronic lymphomas where A+B is standard and active agent C being added (AB vs ABC) in a PFS regulatory driven study. In absence of cure/OS the real question for patients/doctors is AB followed by C at relapse (PFS2) vs ABC (PFS1) all together.”

Yu-Hung Wang:

“The star Nico Gagelmann showcased the promising personalised transplant approach for myelofibrosis patients!”

Graham Collins:

“Falchi: Epcor+R2 R/R FL, longer FU
– 111 pts, med FU now 2y
– v high responses: ORR 96%; CRR 87%
– Prolonged remissions in all risk groups
– No new safety signals
Randomised study ongoing.”

Ajay Major:

“Honorable mention Major PROsASH: long-term PROs aHUS
– 55 pts, 82% current eculizumab, 22% R/R
– hx of dialysis did not affect PROs (hx of relapse did)
– worse cog fxn than general pop
Great to know we can use PROMIS PROs in these cohorts.”

Rahul Banerjee:

“The US myeloma immunotherapy consortium has grown and we even have our own logo now – plus 4 orals and 4 posters at ASH24 !

Thanks Surbhi Sidana, Krina Patel, Dori Shansen for continuing to be our fearless leaders behind the scenes.”

Naveen Pemmaraju:

“Myeloid club with Ross Levine, Sanam Loghavi, Julia Maxson, Aditi Shastri, Saad Usmani, Vincent Rajkumar, Sagar Lonial.”